Clinical
Follow pivotal data releases and trial developments that create new strategic pressure for biotech and pharma operators.
47 signals
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.
CLINICAL
A randomized, open-label trial is underway to evaluate TQB2868 injection and anlotinib hydrochloride in combination with chemotherapy versus placebo.
CLINICAL
The ALCHEMIST trial is evaluating the efficacy of adding pembrolizumab to standard chemotherapy in resected non-small cell lung cancer.
CLINICAL
A Phase 3 trial is underway comparing GammaTile implantation with standard care in patients undergoing GBM excision.
CLINICAL
A Phase 3 study is evaluating the safety and efficacy of L606 in patients with pulmonary hypertension due to interstitial lung disease.
CLINICAL
A phase III trial is investigating whether 6 months of HER2-targeted therapy is more effective than 12 months for HER2-positive breast cancer patients who achieved a pathologic complete response after neoadjuvant chemotherapy.
CLINICAL
A phase 3 trial is evaluating the efficacy and safety of orelabrutinib, CNS-penetrable BTK inhibitor, in patients with non-active Secondary Progressive MS.
CLINICAL
A phase III trial is testing the efficacy of adding Herceptin Hylecta or Phesgo to standard chemotherapy in HER2 positive endometrial cancer.
CLINICAL
A phase III trial is underway to evaluate the efficacy and safety of MEDI5752 in combination with standard chemotherapy in patients with unresectable pleural mesothelioma.
CLINICAL
A Phase III trial is underway to evaluate giredestrant against standard endocrine therapy in ER-positive, HER2-negative early breast cancer.
CLINICAL
A Phase III trial is underway to evaluate the combination of durvalumab and domvanalimab in patients with unresectable NSCLC.
CLINICAL
A phase III trial is testing the addition of cemiplimab to standard surgery for resectable stage III/IV squamous cell skin cancer.
CLINICAL
A phase III trial has been initiated to evaluate Hemay005 for the treatment of moderately to severely active ulcerative colitis in Chinese patients.
CLINICAL
A phase III trial is comparing osimertinib alone versus its combination with bevacizumab in patients with EGFR-mutant non-small cell lung cancer.
COMPETITIVE
A Phase 3 study is underway to evaluate the efficacy and safety of BLU-5937 in adults with refractory chronic cough.
CLINICAL
A Phase III study is underway to evaluate SYHA1813 against investigator's choice treatment in high-grade meningioma patients.
CLINICAL
A phase III trial is evaluating the efficacy of dinutuximab combined with standard chemotherapy and surgery for high-risk neuroblastoma in children.
CLINICAL
CLINICAL
The Phase 3 LITESPARK-012 trial did not meet its dual primary endpoints of progression-free survival and overall survival for the evaluated combination therapies.
CLINICAL
The Phase III METEOROID study demonstrated that ENSPRYNG (satralizumab) reduced the risk of relapses by 68% in MOGAD patients.
STRATEGY
Roche's Q1 2026 sales grew 6% at constant exchange rates, driven by strong demand for innovative medicines, particularly in multiple sclerosis and oncology.
CLINICAL
A phase III trial is evaluating the addition of durvalumab to standard chemotherapy in patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
CLINICAL
A randomized phase III trial is assessing the efficacy of tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy in invasive breast cancer.
CLINICAL
A phase III trial is assessing the efficacy of adding triapine to standard cisplatin and radiation therapy for advanced-stage cervical and vaginal cancers.
CLINICAL
The Phase 3 MagnetisMM-5 trial demonstrated a statistically significant improvement in progression-free survival for ELREXFIO in patients with relapsed or refractory multiple myeloma compared to standard-of-care.
CLINICAL
A Phase III trial demonstrated that Ashwagen® significantly reduced anxiety and stress markers in patients with hypertension.
Showing 1–25 of 47 records